CDSCO Panel Approves Pfizer's Proposal for protocol amendment of Marstacimab

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2024-01-01 12:00 GMT | Update On 2024-03-22 17:09 GMT

New Delhi: The drug major Pfizer has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) for the protocol amendment of Marstacimab.

This came after the drug major Pfizer presented Protocol Amendment 1 dated 22March 2023, Protocol no. B7841008.

The purpose of this clinical trial is to learn about the safety and effects of the study medicine (marstacimab) for the potential treatment of hemophilia in pediatric patients.

Marstacimab is a human Monoclonal Antibody Directed Against Tissue Factor Pathway Inhibitor currently being developed by Pfizer for the treatment of hemophilia A and hemophilia B.

Marstacimab (PF-06741086) is a human monoclonal immunoglobulin G isotype, subclass 1 (IgG1) that targets the Kunitz 2 domain of tissue factor pathway inhibitor (TFPI), a natural anticoagulation protein that functions to prevent the formation of blood clots. Marstacimab is in development as a prophylactic treatment to prevent or reduce the frequency of bleeding episodes in individuals with severe hemophilia A or moderately severe to severe hemophilia B with or without inhibitors.

At the recent SEC meeting for Oncology and Hematology held on 29th and 30th November 2023, the expert panel reviewed the protocol amendment 1 dated 22 March 2023, Protocol no. B7841008.

After detailed deliberation, the committee recommended the approval of the protocol amendment as presented by the firm.

Also Read: Roche Gets CDSCO Panel Nod to Study anti-cancer Drug Inavolisib

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Dr. Divya Colin

Dr. Divya Colin, a Doctor of Pharmacy Graduate with extensive experience in clinical and hospital settings and confidently equipped with diagnostic and therapeutic skills. She also has spread out exposure to Oncology Departments in Mysore Medical College and Research Institute as Oncology Pharmacist. Currently she is building a career in clinical research and clinical data management. She has been a part of Medical Dialogue since January 2022.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

CDSCO Panel Approves Pfizer's Proposal for protocol amendment of Marstacimab

Similar News

Shilpa Pharma Lifesciences Unit-1 successfully completes GMP inspection from Brazilian regulatory authority

Lupin rolls out Nasal spray for rhinorrhea relief in US

Pfizer Told To Conduct Phase IV Trial of Abrocitinib in Indian Adolescents with Atopic Dermatitis

CBI Cracks Down on PCI Chief Montu Patel in College Bribery Scandal

Submit Full Adverse Event Data from Lenvatinib Phase IV Liver Cancer Trial: CDSCO Panel To Eisai Pharma

Over 700 bottles of Codeine Cough Syrup seized, 2 arrested

Massive Rs 1.2 crore Oxytocin seizure in Lucknow, 3 held

High-Alcohol Medicinal Preparations to Come Under Schedule H1: Govt Panel Approves Rule Change